Phase I trial of sublingually administered buprenorphine/naloxone (OX 219) to determine commercial formulation and dose.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2011
At a glance
- Drugs Buprenorphine/naloxone (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics
- 26 Sep 2011 New trial record
- 21 Sep 2011 Results reported in an Orexo media release.